QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

22,525 signal articles · 90 in last 24h · 108,071 total before filter · latest 53m ago
90last 24h
2590last 7d
487● bullish (7d)
237● bearish (7d)
202publishers
AllMacro225Earnings1622M&A119Regulatory15Product10Analyst25
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Rigetti (RGTI) Expands HPE Partnership To Build NSF Backed TangleLab Supercomputer
Simply Wall St.13d agobullish
Rigetti (RGTI) Expands HPE Partnership To Build NSF Backed TangleLab Supercomputer

Rigetti Computing, Hewlett Packard Enterprise and the Pittsburgh Supercomputing Center are teaming up to build TangleLab, a new hybrid quantum classical supercomputer. The system is being developed under a U.S. National Science Foundation grant and is planned as an open testbed for researchers and educators. The collaboration extends Rigetti Computing's existing work with HPE and embeds its hardware into a major academic and government backed computing project. Rigetti Computing...

AT&T (T) Expands D Wave Partnership To Rework Telecom Network Operations
Simply Wall St.13d agobullish
AT&T (T) Expands D Wave Partnership To Rework Telecom Network Operations

AT&T (NYSE:T) has expanded its quantum computing partnership with D-Wave to cover more of its telecom network operations. The agreement focuses on applying quantum tools to outage detection, technician routing, and traffic management across AT&T's network. The move shifts the collaboration from limited pilots to wider operational use within AT&T's infrastructure. AT&T operates one of the largest telecom networks in the United States, with complex infrastructure that depends on efficient...

Merck (MRK) Says KEYTRUDA Beat Chemotherapy In Phase 3 Endometrial Cancer Trial
Simply Wall St.13d agobullish
Merck (MRK) Says KEYTRUDA Beat Chemotherapy In Phase 3 Endometrial Cancer Trial

Merck (NYSE:MRK) reported that KEYTRUDA met its primary endpoint of progression free survival in the Phase 3 KEYNOTE C93 trial for advanced or recurrent endometrial cancer. The company highlighted this as the first time a PD 1 inhibitor has shown a statistically significant benefit over platinum chemotherapy in this patient population. The data are described as a high impact development for Merck's oncology portfolio, with potential implications for future regulatory filings. For investors...

Kilroy Realty (KRC) Tops Q2 FFO Estimates
Zacks13d agobullish
Kilroy Realty (KRC) Tops Q2 FFO Estimates

Kilroy Realty (KRC) delivered FFO and revenue surprises of +2.22% and -0.60%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Bloomberg13d agobullish
BlackRock Dodges AI Bond Flop as $12.3 Billion Debt Deal Rallies

(Bloomberg) -- Bonds that BlackRock Inc. is selling, tied to a Meta Platforms Inc. data center project in Texas, rallied in early trading on Monday before the notes were formally priced, signaling demand for the securities may be stronger than it initially appeared.Most Read from BloombergNvidia’s $750 Billion in Deals Reignite Circular AI FearsDeepSeek Suspends Fundraising After Viral US-China PostsS&P 500 Wobbles as AI Angst Offsets Oil Decline: Markets WrapChina Chipmaker CXMT Jumps 466% in D